346597-03-3

Basic information

• Product Name: 1H-Purine-2,6-dione, 7-[(2-bromophenyl)methyl]-8-chloro-3,7-dihydro-1,3-dimethyl-
• CAS NO: 346597-03-3
• Molecular Formula: C14H12BrClN4O2
• Molecular Weight: 383.632
• Mol File: 346597-03-3.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 1H-Purine-2,6-dione, 7-[(2-bromophenyl)methyl]-8-chloro-3,7-dihydro-1,3-dimethyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Purine-2,6-dione, 7-[(2-bromophenyl)methyl]-8-chloro-3,7-dihydro-1,3-dimethyl-(346597-03-3)
• EPA Substance Registry System: 1H-Purine-2,6-dione, 7-[(2-bromophenyl)methyl]-8-chloro-3,7-dihydro-1,3-dimethyl-(346597-03-3)

Safety Data

• Hazardous Substances Data: 346597-03-3(Hazardous Substances Data)

Upstream product

• 85-18-7 8-chlorotheophylline 
• 22115-41-9 2-(bromomethyl)benzonitrile 
• 3433-80-5 1-Bromo-2-bromomethyl-benzene 

Downstream Products

• 485820-41-5 8-(3-aminopiperidin-1-yl)-7-(2-bromobenzyl)-1,3-dimethyl-3,7-dihydropurine-2,6-dione trifluoroacetate 
• 485821-38-3 8-(3-aminoazepan-1-yl)-7-(2-bromobenzyl)-1,3-dimethyl-3,7-dihydropurine-2,6-dione trifluoroacetate 
• 485820-45-9 (S) 8-(3-aminopyrrolidin-1-yl)-7-(2-bromobenzyl)-1,3-dimethyl-3,7-dihydropurine-2,6-dione hydrochloride 
• 749844-54-0 (S) 8-(3-aminopyrrolidin-1-yl)-7-(2-bromobenzyl)-1,3-dimethyl-3,7-dihydropurine-2,6-dione 

Relevant articles and documents

SUCCINATE SALTS OF HETEROCYCLIC DPP-IV INHIBITORS

The present invention relates to therapeutically active and selective hemisuccinate salts of inhibitors of the enzyme DPP-IV of formula (I), pharmaceutical compositions comprising the salts and the use of such salts for and the manufacture of medicaments for treating diseases that are associated with proteins that are subject to inactivation by DPP-IV, such as type 2 diabetes and obesity.

Method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states

The present invention is related to a method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states comprising administering inhibitors of the enzymes NEP and DPP-IV to individuals suffering from one or m